US 8138351
Treatment of duchenne muscular dystrophy
granted A61PA61P21/00A61P21/04
Quick answer
US patent 8138351 (Treatment of duchenne muscular dystrophy) held by Summit Corporation Plc expires Mon Mar 15 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Summit Corporation Plc
- Grant date
- Tue Mar 20 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 15 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 10
- CPC classes
- A61P, A61P21/00, A61P21/04